Arcturus Therapeutics Holdings Inc’s recently made public that its Chief Scientific Officer & COO Chivukula Pad unloaded Company’s shares for reported $0.3 million on Mar 19 ’24. In the deal valued at $35.01 per share,8,565 shares were sold. As a result of this transaction, Chivukula Pad now holds 490,883 shares worth roughly $15.77 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Chivukula Pad sold 5,000 shares, generating $93,602 in total proceeds. Upon selling the shares at $18.72, the Chief Scientific Officer & COO now owns 499,448 shares.
Before that, Chivukula Pad sold 5,000 shares. Arcturus Therapeutics Holdings Inc shares valued at $128,062 were divested by the Chief Scientific Officer & COO at a price of $25.61 per share. As a result of the transaction, Chivukula Pad now holds 504,448 shares, worth roughly $16.21 million.
Canaccord Genuity initiated its Arcturus Therapeutics Holdings Inc [ARCT] rating to a Buy in a research note published on December 13, 2023; the price target was $90. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. H.C. Wainwright also remained covering ARCT and has increased its forecast on May 11, 2023 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of ARCT
On Tuesday, Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] saw its stock fall -7.65% to $32.13. Over the last five days, the stock has lost -4.83%. Arcturus Therapeutics Holdings Inc shares have risen nearly 1.90% since the year began. Nevertheless, the stocks have risen 104.65% over the past one year. While a 52-week high of $43.81 was reached on 02/27/24, a 52-week low of $15.32 was recorded on 01/05/24. SMA at 50 days reached $36.06, while 200 days put it at $29.64. A total of 0.55 million shares were traded, compared to the trading of 0.33 million shares in the previous session.
Levels Of Support And Resistance For ARCT Stock
The 24-hour chart illustrates a support level at 30.77, which if violated will result in even more drops to 29.41. On the upside, there is a resistance level at 34.48. A further resistance level may holdings at 36.84. The Relative Strength Index (RSI) on the 14-day chart is 37.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.76, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.34%. Stochastics %K at 18.50% indicates the stock is a buying.
How much short interest is there in Arcturus Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Arcturus Therapeutics Holdings Inc stocks on Feb 29, 2024, dropping by -0.15 million shares to a total of 4.22 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 4.37 million shares. There was a decline of -3.55%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 20.97% of the overall stock float, the days-to-cover ratio (short ratio) fell to 10.21.
